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Background/aim: To compare the effectiveness of intraoperative 5 fluorouracil (5-FU) and mitomycin C (MMC) application in
preventing recurrence following primary pterygium excision.
Materials and methods: This was a prospective clinical trial that included 93 patients with primary pterygia assigned to three treatment
groups in which 29 patients received an intraoperative application of 25 mg/mL 5-FU for 5 min, 32 patients received an intraoperative
application of 0.02% MMC for 5 min, and 32 patients underwent only surgical excision (the control group). Follow-up visits were done
on postoperative days 1, 3, 7, 15, and 30, and then every month.
Results: After a mean follow-up of 14 months, the surgical excision recurrence rates in the 5-FU, MMC, and control groups were 27.6%,
12.5%, and 43.75%, respectively. There was a statistically significant difference in the 5-FU and MMC groups when compared with
the control group (chi-square; P = 0.04); however, the difference between the 5-FU and MMC groups was not significant. No serious
complications were seen in the 5-FU and MMC groups.
Conclusion: Intraoperative application of MMC and 5-FU is effective and safe for the prevention of recurrence. Our findings suggest
that MMC is more potent for the prevention of recurrence and it causes less complaints than 5-FU.
Key words: Adjunct therapies, antimetabolites, complications, recurrence, pterygium excision

1. Introduction
Pterygium is defined as an extension of fibrovascular
growth from the conjunctiva onto the cornea. It can cause
chronic irritative symptoms, cosmetic problems, and
vision impairment (1,2).
Many surgical techniques have been developed for the
treatment of pterygium. However, the recurrence rates are
between 24% and 89% following simple pterygium excision
(1–6). Because of these high recurrence rates, the use of
adjunct therapies such as beta radiation, antimetabolites
like mitomycin C (MMC) and 5-fluorouracil (5-FU), and
conjunctival autograft has been advocated.
Direct comparisons between studies is difficult for
various reasons, including a wide range of sample sizes,
whether primary or recurrent pterygia were studied, and
differences in the definition of pterygium recurrence
and follow-up periods. These reasons contribute to the
conflicting results that are sometimes observed in different
studies (7).
The main objective of this study was to compare
concurrent intraoperative 5-FU or MMC application with
* Correspondence: altayye@yahoo.com

simple excision in the treatment of primary pterygium in
terms of recurrence prevention.
2. Materials and methods
Ninety-three patients with primary pterygium (47 women
and 46 men) who underwent surgery were included.
Indications for surgery were chronic irritation, cosmetic
problems, and vision impairment.
At the initial visit all patients were examined, and
the size and location of pterygia were defined. Pterygia
were classified as atrophic type (type 1), noninflamed
type (type 2), and inflamed type (type 3) according to
clinical appearance. If the pterygium tissue was densely
vascularized, hyperemic, and edematous, it was classified
as inflamed. If the pterygium was less vascularized,
nonedematous, and without edema, then it was classified as
noninflamed. The atrophic type was defined as a pterygium
with minimal vascularization, without hyperemia, and
without edema.
Patients were divided into three groups based on
treatment protocol (5-FU, MMC, and control). The same
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surgeon performed all surgeries. This study was approved
by the institutional review board of the hospital, and it
was in accordance with the principles of the Declaration
of Helsinki. All patients gave informed consent before the
study.
We used the technique defined previously by Altay et
al. (8).
In the 5-FU group, 5-FU was applied intraoperatively
to 29 eyes of 29 patients, including 13 women and 16 men.
After cleaning the lids and conjunctiva with povidoneiodine solution, 0.4% benoxinate was dripped onto the
conjunctiva for anesthesia. Lidocaine 2% was injected
subconjunctivally under the body of the pterygium. The
head of the pterygium was separated from the cornea with
the help of two hooks. The corneal surface was flattened by
using a number 15 scalpel. Following the excision of the
head of the pterygium, minimal thermal coagulation was
applied to the limbus. A 3 × 4 mm sponge soaked into 25
mg/mL 5-FU solution was then laid onto the scleral bed
where the pterygium was excised. The conjunctiva and
Tenon’s capsule were covered over the sponge and kept in
contact for 5 min. Extreme care was taken not to apply
the antimetabolite agent on the cornea. After this period,
the sponge was removed and the area was rinsed by using
a 20 mL lactated-Ringer solution. Then conjunctiva was
sutured with a 10/0 nylon stitch by leaving a 3 mm bare
sclera next to the limbus. Following the application of
antibiotic pomade, the eye was covered and the operation
was completed (8).
In the MMC group, MMC was applied intraoperatively
to 32 eyes of 32 patients, including 14 women and 18 men.
Following pterygium excision, a sponge soaked into 0.02%
MMC solution was applied onto the scleral bed where
the pterygium was excised. The conjunctiva and Tenon’s
capsule were covered over the sponge and kept in contact
for 5 min. After this period, the sponge was removed and
the area was rinsed by using a 20 mL lactated-Ringer
solution. The conjunctiva was then sutured with a 10/0
nylon stitch by leaving a 3 mm bare sclera next to the
limbus. Following the application of antibiotic pomade,
the eye was covered and the operation was completed (8).
In the control group, which included 20 women and
12 men, following excision of the head of the pterygium,
the conjunctiva was sutured by leaving a 3 mm bare sclera
next to the limbus. The procedure was finished by covering
the eye after antibiotic pomade was applied.
Beginning from the first day after surgery, antibiotic
drops were applied four times a day until complete
epithelization. Topical steroid drops were also applied four
times a day; they were gradually discontinued within 4
weeks by tapering the dose (8).
Patients were scheduled for follow-up visits on days 1,
3, 7, 15, and 30, and then monthly. At each visit patients
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were examined for the presence of corneal epithelial
disorders, punctate keratitis, anterior chamber reaction,
and recurrence. Patient complaints such as pain, irritation,
watering, and photophobia were recorded. Recurrence
was defined as the growth of fibrovascular tissue over the
area of the previous pterygium, extending 1 mm or more
onto the cornea (as observed with slit-lamp) by pulling of
the conjunctiva (8).
Statistical analyses were performed using SPSS 15.
The variables were investigated using visual and analytical
methods (Shapiro–Wilk test) to determine whether or
not they were normally distributed. Descriptive analyses
were presented using means and standard deviations for
normally distributed variables. Statistical evaluation was
done by using one-way ANOVA, Student’s t-test, and chisquare test. P < 0.05 was considered statistically significant.
3. Results
We compared age, size of pterygium, type of pterygium,
and sex in patients with and without recurrence following
surgery. The recurrence patients were younger when their
mean age was compared with that of the other patients.
The size of the pterygium was bigger in patients with
recurrence. Recurrence in type 3 pterygia was higher
than in type 2 ones, and there was no recurrence in type
1 pterygia. Recurrence rates of males and females were
similar (Table 1).
The 5-FU group consisted of 29 patients, 13 women
and 16 men, with a mean age of 45.44 (and a range of 24–
73). The types of pterygium of these 29 patients were as
follows: 1 atrophic (type 1), 20 noninflamed (type 2), and
8 inflamed (type 3) (Table 2).
The MMC group consisted of 32 patients, 14 women
and 18 men, with a mean age of 47.71 (and a range of 18–
73). The types of pterygium of these 32 patients were as
follows: 3 atrophic (type 1), 20 noninflamed (type 2), and
9 inflamed (type 3) (Table 2).
The control group consisted of 32 patients, 20 women
and 12 men, with a mean age of 48.65 (and a range of 25–
80). The types of pterygium of these 32 patients were as
follows: 2 atrophic (type 1), 19 noninflamed (type 2), and
11 inflamed (type 3) (Table 2).
There were no significant differences between the
groups in terms of sex (chi-square, P = 0.24), type of
pterygium (chi-square, P = 0.85), age (one-way ANOVA,
P = 0.61), and age groups (chi-square, P = 0.33) as seen on
Table 2.
In the 5-FU group, the mean size of the extension of
the pterygium over the cornea was 3.15 mm (with a range
of 2–4.5 mm); in the MMC group it was 3.20 mm (with
a range of 2–5 mm); and it was 3.50 mm (with a range of
2.5–5 mm) in the control group. There was no significant
difference among the groups in terms of pterygium size
and recurrence rate.
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Table 1. Factors affecting pterygium recurrence.
Factors

Recurrence

P

Present

Absent

Age (years; mean ± SD)

41.88 ± 11.13

50.71 ± 12.87

0.003*

Size of pterygium (mm; mean ± SD)

3.75 ± 0.72

3.12 ± 0.62

0.0001*

Type 1 (%)

0 (0)

8

Type 2 (%)

12 (20.7)

46

Type 3 (%)

14 (51.9)

13

Male (%)

13 (28.3)

33

Female (%)

13 (27.7)

34

Types of pterygium
0.002**

Sex
0.94

*Statistically significant difference, Student’s t-test.
**Statistically significant difference, chi-square.

Table 2. Patient mean ages, age groups, sex, and types of pterygia among the treatment
groups.
Treatment groups
Variables

5-FU group
n = 29

MMC group
n = 32

Control group
n = 32

Mean age (years)

45.44

47.71

48.65

10–20

1

0

0

21–30

0

5

2

31–40

7

6

5

41–50

13

9

9

51–60

7

5

8

>60

4

4

8

Women

13

14

20

Men

16

18

12

Type 1

1

3

2

Type 2

20

20

19

Type 3

8

9

11

Age groups

Sex

Pterygium type

5-FU: 5-fluorouracil.
MMC: mitomycin C.
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Twenty-nine patients in the 5-FU group were followed
for an average of 14 months (with a range of 10–18
months) and 8 (27.6%) had a recurrence. Of these eight,
the types of primary pterygia were type 2 in two and type
3 in six patients.
Thirty-two patients in the MMC group were followed
for an average of 14 months (with a range of 12–18
months) and 4 (12.5%) had a recurrence. Of these four,
the types of primary pterygia were type 2 in two and type
3 in two patients.
Thirty-two patients in the control group were followed
for an average of 14 months (with a range of 12–17 months)
and 14 (43.75%) had a recurrence. Of these fourteen, the
types of primary pterygia were type 2 in eight and type 3
in six patients (Table 3).
The number of recurrences was lower in the 5-FU
and MMC groups when compared with the controls (chisquare test, P = 0.04), but there was no significant difference
between the 5 FU and MMC groups (Table 3). When we
compared the recurrences between groups in terms of
types of pterygia, significant differences were observed.
However, this finding should be interpreted with caution,
since chi-square results may be invalid because more than
20% of the cells, when comparing recurrences of type 3
pterygia among the groups, had an expected cell count of
less than five.
The duration of recurrence in the MMC, 5-FU, and
control groups was between 2.5 and 4 months, 2.5 and
5 months, and 2 and 4 months, respectively. There was

no difference between the groups in terms of recurrence
duration (one-way ANOVA, P = 0.30).
Comparisons of patient complaints following treatment
among the groups are presented in Table 4. Pain and
irritation symptoms were seen relatively more frequently
in the 5-FU group (77.3%); however, this difference did
not reach a statistical significance (P = 0.77). Pain and
irritation were seen most commonly during the first 1–2
weeks following treatment.
The punctate epithelial staining rate of the cornea was
significantly lower in the control group when compared
with the 5-FU and MMC groups (P = 0.02).
The rate of photophobia was higher in the 5-FU group,
but the difference was not significant (P = 0.06).
The rate of watering was not different among the
groups (P = 0.08).
4. Discussion
Although the approach to mild symptoms can be
conservative, the main treatment of pterygium is surgical
excision. However, the major problem following surgery is
the high recurrence rates (1–6).
Many factors such as type of pterygium, age of the
patient, climatic characteristics, method of surgery, and
the experience of the surgeon may affect the recurrence
rates following surgery. Our study showed that pterygium
recurrences were seen in younger patients, in patients
with larger pterygia, and in patients with inflamed type
pterygia.

Table 3. Recurrence rates and types of recurrent pterygia among the treatment groups.
Recurrence rates in treatment groups
5-FU group
n = 29

MMC group
n = 32

Control group
n = 32

Types of recurrence
Pterygia

Numbers
(Percentages)

Numbers
(Percentages)

Numbers
(Percentages)

Type 1

0/1
(0%)

0/3
(0%)

0/2
(0%)

Type 2*

2/20
(10%)

2/20
(10%)

8/19
(42.1%)

Type 3**

6/8
(75%)

2/9
(22.2%)

6/11
(54.5%)

Total***
****

8/29
(27.6%)

4/32
(12.5%)

14/32
(43.75%)

* (P = 0.33, chi-square).
** (P = 0.08, chi-square); more than 20 % of cells in this subtable have an expected cell count of less than 5.
The chi-square results may be invalid.
*** (P = 0.04, chi-square).
**** (P = 0.13, chi-square); a comparison between the 5-FU and MMC groups.
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Table 4. Patient complaints during follow-up among the treatment groups.
Treatment groups
Patient complaints

5-FU
(%)

MMC
(%)

Control
(%)

P

Pain and irritation

77.3

68

71

0.77

Punctate epithelial staining

35

20

4

0.02*

Photophobia

52

19

33.3

0.06

Watering

68

36.4

58.1

0.08

* Statistically significant difference, chi-square.

Every recurrence causes loss of conjunctival tissue,
limits the movements of the extraocular muscles, or forms
scar tissue, in addition to the occurrence of the same
pathology. Therefore, the definitive therapy of pterygium
by primary surgery is extremely important (5,9–14) When
the surgical excision is applied alone for the treatment
of primary or recurrent pterygium, it results in high
recurrence rates, as reported in different studies (30%, 70%,
and 80%) (9–11). Since the recurrence rates are high with
surgical excision alone, today some specific techniques
and adjunct treatments following surgery are used in
order to decrease those rates. These include intraoperative
and postoperative MMC, conjunctival autografting, and
amnion membrane grafting (1–6,15).
Several studies are reported about the use of 5-FU
and MMC in pterygium surgery with different results (9–
11,14). Any direct comparison of clinical trials is difficult
because of the variability of confounding factors such as
differences in the dose and duration of application of the
drugs, whether the pterygium is primary or secondary,
type of pterygium, differences in the definition of
recurrence, and differences in follow-up periods. In our
study, we included only patients with primary pterygia.
MMC, a chemotherapeutic agent, acts by inhibiting
DNA synthesis, mitosis, and protein synthesis. Its current
application in pterygium surgery, glaucoma surgery, and
corneal refractive surgery is on the rise because of its
modulatory effects on wound healing (15).
The recurrence rates of pterygia with the use
of intraoperative and postoperative mitomycin-C
were between 0% and 38%. Complications such as
scleral ulceration and thinning, delayed conjunctival
epithelialization, iritis, corneoscleral and vitreoretinal
toxicity, uveitis, and glaucoma were reported with MMC
therapy (16–19).
Many studies compared intraoperative MMC and
postoperative MMC application with bare sclera excision.
The data from all studies indicate that the use of MMC

reduces pterygium recurrence as compared with bare
sclera excision for primary pterygia (20). One study (21)
reported a 15.9% recurrence rate with intraoperative 0.02%
MMC application for 5 min in the treatment of primary
pterygia. Another study reported a 5.76% recurrence
rate by using the same method (22). We found a 12.5%
recurrence rate in our MMC group without any serious
complications. The difference may be due to the type of
pterygia in the studied patients.
The 5-FU is a pyrimidine analogue that inhibits DNA
synthesis and is active on the synthesis phase of the cell
cycle. Its ability to reduce fibroblastic proliferation and
subsequent scarring has made it an important adjunct in
ocular and periorbital surgeries (23). Studies showed that
short-term application (for 5 min) of high doses of 5-FU
was effective in inhibiting the long-term proliferation of
Tenon’s capsule fibroblasts (19,23). However, intraoperative
application of low doses of 5-FU in primary pterygium
surgery showed that it was inefficient in preventing
recurrences. In that study, a low dose of 5-FU (10 mg/mL)
solution was applied for 5 min (24). In our study, we applied
5-FU solution at a higher concentration (25 mg/mL) for 5
min intraoperatively. We found that the recurrence rate in
the 5-FU group was 27.6%. This finding may be due to the
higher concentrations of 5-FU in our study. Akarsu et al.
studied intraoperative application of 5-FU (25 mg/mL, for
3 min) in primary pterygium surgery, and they found a
25% recurrence rate (25). Kareem et al. applied 50 mg/mL
5-FU solution for 3 min in primary pterygium and they
found a 28% recurrence rate (26). These results are similar
to ours.
Complaints such as pain and irritation, punctate
epithelial staining, photophobia, and watering are
documented in Table 3. Complaints were more common
in the 5-FU group, but the disturbance did not last for a
long time, and there were no serious ocular complications.
The intraoperative use of MMC and 5-FU has the
advantage of direct monitoring of drug exposure when
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compared with postoperative regimens, which require
patient adherence. We applied sponges soaked with MMC
and 5-FU directly onto the undersurface of the surrounding
residual conjunctival bed, taking care not to spill any excess
MMC and 5-FU onto the cornea and limbus; this may be
the reason for the absence of serious complications. Altay
et al. reported that intraoperative 5-FU and MMC had no
pathologic effects on the neighboring conjunctiva; their
effects were limited only to the area on which they were
applied (8).
Our study and the other studies using intraoperative
0.02% MMC application for 5 min showed that MMC
application was a safe and efficient way of preventing
recurrences in pterygium surgery. Moreover, the

recurrence rate with MMC was much lower than that with
5-FU (20,21,26).
We showed that pterygium type is important in
pterygia recurrence rates. The inflamed type pterygium
is more prone to recurrences following surgery. It may be
useful to treat this type of pterygium with topical steroids
and antiinflammatory agents prior to surgery. Younger
patients and patients with larger pterygia are also more
prone to recurrence.
In conclusion, single intraoperative applications of
MMC and 5-FU are effective and safe for recurrence
prevention in pterygium surgery. We think that MMC is
more potent and it caused less complaints than 5-FU.
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